Wire · opportunities
Novartis' remibrutinib cuts relapse rates by up to 35% in Phase III multiple sclerosis trials
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Novartis' oral BTK inhibitor remibrutinib significantly reduced relapse rates by over 30% in Phase III trials for relapsing multiple sclerosis compared to teriflunomide, with strong MRI and disability progression benefits and a favourable safety profile. Novartis plans to seek global regulatory approval for remibrutinib in RMS following these positive results.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 24 Oct 2026 and 26 Oct 2026.
◆ ◆ The Wire takeaway
You now have a new oral treatment option for relapsing multiple sclerosis with a strong safety profile to compete against Roche's fenebrutinib. Expect regulatory windows to open soon, making it critical to engage neurologists and payers early.
◆ Coverage
2 sources · first reported 24 Oct 2026 · latest 26 Oct 2026
◆ Related on Wire
◆ Topics